Oct 16, 2023 7:00 am EDT Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference
Oct 3, 2023 7:00 am EDT Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa
Sep 21, 2023 7:00 am EDT Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
Sep 18, 2023 7:00 am EDT Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
Sep 14, 2023 7:01 am EDT Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
Sep 1, 2023 7:00 am EDT Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
Aug 29, 2023 1:43 pm EDT Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
Aug 23, 2023 7:00 am EDT Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis